Skip to main content

Are Older Persons Being Over Treated for Nonmelanoma Skin Cancer?


One could argue that nonmelanoma skin cancer should not even be called Cancer.  While under the microscope it looks like cancer, it doesn't really act like what most people think of when they hear the word, "Cancer."  Unlike the much less common melanoma or cancers of other organs, plain old run of the mill skin "cancer" almost never metastasizes (ie, spread to different organs).  It usually grow very slowly, and is almost never fatal.  Often it is asymptomatic and has no impact on quality of life.  This condition just does not deserve the dread and fear associated with word, "Cancer."

Since nonmelanoma skin "cancer" usually poses no threat at all to survival, the reason to treat the "cancer" is to improve well being.    We can enhance well being by treating a "cancer" that is currently bothersome to the patient, or will become bothersome if it grows and expands.  But this is where it gets interesting.  Since many of these "cancers" grow very slowly, some will never become problematic in the patient's lifetime.  This is a very important consideration as skin "cancer" is predominantly a disease of older people.  Many persons with skin "cancer" are very old or very frail.  Patients with limited life expectancies may do fine with either minimal treatment, or perpaps even no treatment at all.  This suggests that the best treatment for a particular "cancer" needs to consider the age and health status of the patient. 

But, in actual practice, when a patientt has skin "cancer", does the treating provider consider the individual characteristics of the patient in front of them, or do they use a one size fits all approach, focusing on the "cancer", but not the person?

A fascinating study in JAMA Internal Medicine suggests we are overtreating skin "cancer" in patients who are very old or very frail because of a one size fits all approach to treatment.  The study was led by Dr. Eleni Linos, with senior author Dr. Mary-Margaret Chren, both Dermatologists at UCSF.  They examined treatment of patients with nonmelanoma skin "cancer" at UCSF and the San Francisco VA.  They did a very interesting comparison of how skin "cancer" treatment varied in patients with long vs limited life expectancies.  The limited life expectancy group included persons over the age of 85, or with many medical conditions. 

They found:

  • Patients are almost always treated.  The no treatment option was chosen for only 3% of skin "cancers".  Of note, 60% of "cancers" were not on the face, and in only 22% of cases were patients significantly bothered by their "cancer", suggesting that very conservative management of deferred treatment should have been reasonable in at least some patients.
  • Patient characteristics are not considered in the treatment decision.  There are a number of treatment options for patients ranging from very simple and less invasive options like destruction (i.e., freezing) to surgical options.  The most invasive option, Moh's surgery was used in 34% of patients.  Moh's surgery takes on average 3 hours and is also the most expensive option.  Patients with long life expectancies and short life expectancies were equally likely to get Moh's surgery.  Thus very advanced age or severe co-existing disease seemed to make not one iota of difference in treatment. 
This study suggests we need to revisit how we treat skin cancer, especially in the very old.  Perhaps we should at least inform patients that deferring treatment may be a viable option.  When treatment is deferred, patients have the option of getting treated later if they change their mind, or the skin cancer seems to be growing.  When the skin cancer is treated, patients need to have more of a say in their treatment options, and given the choice of less invasive and bothersome treatments with less risk of complications.


by: Ken Covinsky (@geri_doc)

Comments

Toni Kamins said…
Lumping all non-melanoma skin cancers into one group is as dangerous as it is erroneous. While basal cell carcinomas are usually slow growing and not life threatening, squamous cell carcinomas that originate in the skin can and do metastasize to other organs and can be deadly.
Dan Matlock said…
Cognitive psychologist and Nobel prize winner Dan Kahneman suggests that when someone asks a question that is too hard (like "are the benefits of treating skin cancer in frail older adults worht the risks and costs?") that we as humans substitute an easier question (like "is cancer bad?" or "do I like cancer?")

Toni Kamins, you have done exactly this with your comment. You have substituted a thoughtful cognitive question regarding the treatment of skin cancer with an emotionally laden question of "is cancer bad?"

This is one of the problems with the entire field of cancer prevention. Any time someone poses a thoughtful question about trade-offs, which is hard to think about, the backlash always relates to the easier question and turns into a thoughtless, emotionally laden journey into "cancer is bad."

Yes, cancer is bad...but that's not the question...

So annoying.
Stacy Fischer said…
I forwarded this post along to my dear friend and dermatologist extradinaire shared with me a wonderful story that really exemplifies the ethos of this geri-pal post. An very elderly patient came to see her for the first time. As he removed his ball cap she was stunned to see anenormous squamous cell lesion that covered most of the top of his head. His arms were simply emcrusted in cancer. Not even sure where to begin she said to him "What is bothering you today" His daughter was clearly troubled by the large lesion on his head. He pointed to a single 1 cm lesion on his arms that was itching. Then they had a thoughtful discussion about the risks and considerable burdens of treating the other skin cancers ("Cancer?! the patient exclaimed)and then decided to simply freeze the one arm lesion that was itching. he left her office smiling, slipping his ball cap back on his head.
Toni Kamins said…
Dan Matlock:

Clearly you misread my post and inferred according to your own agenda. So annoying.

Popular posts from this blog

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …

Opening the Black Box of LTACs: Podcast with Anil Makam

What happens in Long Term Acute Care Hospitals, or LTACs (pronounced L-tacs)?  I've never been in one.  I've sent patients to them - usually patients with long ICU stays, chronically critically ill, with a gastric feeding tube and a trach for ventilator support.  For those patients, the goals (usually as articulated by the family) are based on a hope for recovery of function and a return home.

And yet we learn some surprising things from Anil Makam, Assistant Professor of Medicine at UCSF.  In his JAGS study of about 14,000 patients admitted to LTACHs, the average patient spent two thirds of his or her remaining life in an institutional settings (including hospitals, LTACs and skilled nursing facilities).  One third died in an LTAC, never returning home.

So you would think with this population of older people with serious illness and a shorter prognosis than many cancers, we would have robust geriatrics and palliative care in LTACs?  Right? Wrong.

3% were seen by a geriatrici…

Length of Stay in Nursing Homes at the End of Life

One out of every four of us will die while residing in a nursing home. For most of us, that stay in a nursing home will be brief, although this may depend upon social and demographic variables like our gender, net worth, and marital status. These are the conclusions of an important new study published in JAGS by Kelly and colleagues (many of whom are geripal contributors, including Alex Smith and Ken Covinsky).

The study authors used data from the Health and Retirement Study (HRS) to describe the lengths of stay of older adults who resided in nursing homes at the end of life. What they found was that out of the 8,433 study participants who died between 1992 and 2006, 27.3% of resided in a nursing home prior to their death. Most of these patients (70%) actually died in the nursing home without being transferred to another setting like a hospital.

 The length of stay data were striking:

the median length of stay in a nursing home before death was 5 months the average length of stay was l…